Author:
Zwaan ChM,Reinhardt D,Jürgens H,Huismans D R,Hählen K,Smith O P,Biondi A,Wering E R van,Feingold J,Kaspers G J L
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference6 articles.
1. Sievers EL, Appelbaum FR, Spielberger RT, Forman SJ, Flowers D, Smith FO, Shannon-Dorcy K, Berger MS, Bernstein ID . Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 1999; 93: 3678–3684.
2. Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H, Karanes C, Theobald M, Bennett JM, Sherman ML, Berger MS, Eten CB, Loken MR, Van Dongen JJ, Bernstein ID, Appelbaum FR . Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001; 19: 3244–3254.
3. Putti MC, Rondelli R, Cocito MG, Arico M, Sainati L, Conter V, Guglielmi C, Cantu-Rajnoldi A, Consolini R, Pession A, Zanesco L, Masera G, Biondi A, Basso G . Expression of myeloid markers lacks prognostic impact in children treated for acute lymphoblastic leukemia: Italian experience in AIEOP-ALL 88–91 studies. Blood 1998; 92: 795–801.
4. Hinman LM, Hamann PR, Wallace R, Menendez AT, Durr FE, Upeslacis J . Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. Cancer Res 1993; 53: 3336–3342.
5. Zwaan ChM, Kaspers GJL, Pieters R, Ramakers-Van Woerden NL, Den Boer ML, Wnsche R, Rottier MMA, HΩhlen K, Van Wering ER, Janka-Schaub GE, Creutzig U, Veerman AJP . Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB-types and comparison with acute lymphoblastic leukemia. Blood 2000; 96: 2879–2886.
Cited by
58 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献